Sharemaestro company-news research for Enlivex Therapeutics Ltd (ENLV), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest ENLV news and sentiment
Enlivex Therapeutics Ltd
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score49Neutral is 50
Early balanced news score
29/100 evidence confidence
100% direct company focus
4 current stories across 2 publishers
Current company news
Early balanced news score
4 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone42/100
→
Published 30-day score49/100
Latest source headline
Enlivex Therapeutics stock gains on upcoming Q1 2026 earnings and steep year-to-date decline
AD HOC NEWS · 20 Sep 2026 16:49
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
4 current stories are mapped specifically to ENLV.
What limits the score
Only 2 publishers currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.136.
Confidence is 29/100, below the threshold for a firm score.
49/100
News scoreEarly balanced news score
29/100
Confidencethin evidence
100%/100
Company news4 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
24 Aug08 Sep22 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence3
0.136 after freshness weightingSource breadth40
2 independent publishersCompany relevance100
share tied directly to this companyFreshness69
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix5
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks13 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
27 Mar23 Jun18 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
18 Sep 202650USD 0.8066-15.9%
11 Sep 202650USD 0.9595-12.8%
04 Sep 202650USD 1.1-18.5%
28 Aug 202649USD 1.35-8.2%
21 Aug 202650USD 1.47-7.0%
14 Aug 202651USD 1.58-24.0%
07 Aug 202653USD 2.08-0.5%
31 Jul 202648USD 2.09-50.2%
Provisional evidence
News subjects
What is shaping the score
Earnings422 stories · 50%
Market update502 stories · 50%
Source mix
Where the evidence comes from
TradingView411 stories · 25%
AD HOC NEWS421 stories · 25%
Zacks501 stories · 25%
Kalkine501 stories · 25%
Recurring subjects
Subjects appearing most often
Life Sciences1Earnings1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
22 Jun50 neutral21 Sep 15:41
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 21 Sep 15:41 | 49 | +0 | 28/100 (-2) | 4 (0) | Provisional |
| 20 Sep 23:59 | 49 | -1 | 30/100 (+10) | 4 (-7) | Provisional |
| 01 Sep 23:59 | 50 | +0 | 20/100 (-3) | 11 (+1) | Provisional |
| 29 Aug 23:59 | 50 | +1 | 23/100 (-5) | 10 (-14) | Provisional |
| 25 Aug 23:59 | 49 | -2 | 28/100 (+7) | 24 (-8) | Provisional |
| 14 Aug 23:59 | 51 | +0 | 21/100 (0) | 32 (+1) | Provisional |
| 13 Aug 23:59 | 51 | -1 | 21/100 (-3) | 31 (+1) | Provisional |
| 11 Aug 23:59 | 52 | -1 | 24/100 (-5) | 30 (0) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#142Tone
AD HOC NEWSDirect company coverageScored from headline
Enlivex Therapeutics stock gains on upcoming Q1 2026 earnings and steep year-to-date decline
- Published
- 20 Sep 2026 16:49
- News subject
- Earnings
- Why this score
- Operating deterioration
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 52/100
- 30-day weight
- 97.4% of the score · 1.0d old
- Duplicates
- 1 consolidated
#2—Not directional
ZacksDirect company coverageScored from headline
Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
- Published
- 01 Sep 2026 13:55
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.1d old
- Duplicates
- 1 consolidated
#3—Not directional
KalkineDirect company coverageScored from headline
Enlivex Therapeutics Ltd (NASDAQ: ENLV) Stock Price, News & Analysis
- Published
- 29 Aug 2026 02:14
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.6d old
- Duplicates
- 1 consolidated
#441Tone
TradingViewDirect company coverageStored article
Enlivex Ltd expected to post a loss of 31 cents a share - Earnings Preview
Enlivex Ltd is anticipated to report an earnings loss of 31 cents per share. This information comes from an earnings preview, and the full article is available through a subscription service on TradingView.
EarningsLife Sciences
- Published
- 25 Aug 2026 19:45
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 2.6% of the score · 26.8d old
- Duplicates
- 1 consolidated
Earlier company news
ENLV news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Jul
25
2026
TradingKeyArchivedNeutral tone
Enlivex Therapeutics Ltd (ENLV) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Enlivex Therapeutics Ltd (ENLV), listing its major shareholders and institutional holdings. It shows that Gems Foundation, Token Factory, Sobrinia Ltd, Heaven Consulting Corp, and Alfa Ltd are the largest shareholders, holding significant percentages. The report also provides a breakdown of shareholder types and historical institutional ownership data over several quarters.
Financial MarketsLife Sciences
- Published
- 25 Jul 2026 19:10
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
25
2026
TradingKeyArchivedNegative tone
ENLV|Enlivex Therapeutics Ltd|Price:4.200|Chg%:-0.160
Enlivex Therapeutics Ltd (ENLV) is currently trading at $4.200, down 3.67%. Despite weak fundamentals, the company has high growth potential and is considered fairly valued in the Biotechnology & Medical Research industry. Analysts provide a "Buy" rating with a target price of $300.00, indicating significant upside potential.
EarningsFinancial MarketsLife Sciences
- Published
- 25 Jul 2026 08:17
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
23
2026
MarketBeatArchivedNegative tone
Short Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Declines By 98.2%
Short interest in Enlivex Therapeutics (NASDAQ:ENLV) significantly decreased by 98.2% to 26,452 shares as of July 15, down from 1.51 million shares at the end of June. The short-interest ratio is now 0.4 days, representing about 0.2% of shares sold short. Despite mixed analyst sentiment, with one firm upgrading to strong-buy and another maintaining a buy rating with a $300 price target, the stock has been trading near its 52-week low of $4.08.
EarningsFinancial MarketsLife Sciences
- Published
- 23 Jul 2026 02:10
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
22
2026
The Globe and MailArchivedNeutral tone
Enlivex Reveals $1.1 Billion RAIN Token Treasury and $66.16 NAV Per Share
Enlivex announced an update on its RAIN token-based treasury, reporting a net asset value per ordinary share of $66.16 as of July 18, 2026. The company holds approximately 79.55 billion RAIN tokens valued at $1.1 billion. While maintaining a significant digital asset portfolio, Enlivex's core operations remain focused on clinical-stage immunotherapy, specifically the Allocetra program.
BlockchainEarningsFinancial MarketsLife Sciences
- Published
- 22 Jul 2026 09:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
21
2026
The Manila TimesArchivedNeutral tone
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
Enlivex Ltd. announced an update on its RAIN token holdings as of July 18, 2026. The company reported a net asset value (NAV) per ordinary share of $66.16 and held 79,550,593,122 RAIN tokens, collectively valued at approximately $1.1 billion. Enlivex is a longevity company that combines developing advanced clinical-stage immunotherapy, Allocetra™, with a prediction markets treasury strategy built around the Rain protocol.
BlockchainEarningsFinanceLife Sciences
- Published
- 21 Jul 2026 08:11
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
Jul
20
2026
Stock TitanArchivedNeutral tone
Enlivex’s Net Asset Value Per Share Was $66.16 on July 18
Enlivex (NASDAQ: ENLV) reported its net asset value (NAV) per ordinary share was $66.16 as of July 18, 2026. The company held over 79.5 billion RAIN tokens, valued at approximately $1.1 billion, based on CoinMarketCap closing prices. These unaudited mark-to-market valuations are part of Enlivex's dual strategy, combining clinical-stage Allocetra immunotherapy programs with a prediction markets treasury strategy centered on the Rain protocol.
BlockchainEarningsFinancial MarketsLife Sciences
- Published
- 20 Jul 2026 13:11
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
20
2026
Stock TitanArchivedNeutral tone
Enlivex (Nasdaq: ENLV) details $1.1B RAIN token holdings and NAV
Enlivex Ltd. (Nasdaq: ENLV) announced an update on its digital asset treasury, reporting a net asset value per ordinary share of $66.16 as of July 18, 2026. The company holds approximately 79.55 billion RAIN tokens, valued at about $1.1 billion. This strategy combines its clinical development of Allocetra, an immunotherapy for aging-related inflammatory conditions, with exposure to the decentralized prediction markets ecosystem.
BlockchainFinanceFinancial MarketsLife Sciences
- Published
- 20 Jul 2026 13:11
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
10
2026
timothysykes.comArchivedLegacy headline · tone unscoredLegacy source lookup
Enlivex Ltd. (ENLV) Stock Price | Live Quotes & Charts | NASDAQ
- Published
- 10 Jul 2026 14:35
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
07
2026
TradingViewArchivedLegacy headline · tone unscoredLegacy source lookup
Enlivex Ltd. Actuals & Estimates (NASDAQ:ENLV)
- Published
- 7 Jul 2026 06:36
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
25
2026
Stock TitanArchivedLegacy headline · tone unscoredLegacy source lookup
Enlivex token gets Gate listing, widening access to its $1.14B treasury asset
- Published
- 25 Jun 2026 08:34
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
23
2026
TradingKeyArchivedLegacy headline · tone unscoredLegacy source lookup
Enlivex Therapeutics Ltd (ENLV) Technical Analysis: Support, Resistance, Indicators & Moving Averages
- Published
- 23 Jun 2026 19:45
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
23
2026
TradingKeyArchivedLegacy headline · tone unscoredLegacy source lookup
Enlivex Therapeutics Ltd (ENLV) Risk Assessment: Volatility, Financial Risk & Investment Risk
- Published
- 23 Jun 2026 10:18
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
22
2026
Stock TitanArchivedLegacy headline · tone unscoredLegacy source lookup
[6-K] Enlivex Ltd. Current Report (Foreign Issuer) | ENLV SEC Filing - Form 6-K
- Published
- 22 Jun 2026 18:01
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
22
2026
AD HOC NEWSArchivedLegacy headline · tone unscoredLegacy source lookup
ENLV Stock - weekly outlook with no verified hook
- Published
- 22 Jun 2026 09:31
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Provider matches checked
Provider mentions not used in the score
A news provider linked these stories to ENLV, but the headline and available text are not mainly about Enlivex Therapeutics Ltd. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of ENLV sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.